[HTML][HTML] Pharmaceutical interventions in prescriptions for patients admitted with chronic renal failure

P Arrabal-Durán, ME Durán-García… - Nefrología (English …, 2014 - revistanefrologia.com
Background: Chronic Renal Failure (CRF) is a disease that requires determined
medications dosages to be adjusted. Objectives: To assess the characteristics of …

Switching to a rilpivirine/emtricitabine/tenofovir single‐tablet regimen in RNA‐suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety …

P Arrabal‐Durán… - … Journal of Clinical …, 2017 - Wiley Online Library
Objectives This study evaluates the effectiveness, safety and costs of switching to a
rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) regimen in treatment …

DI-059 Use, effectiveness and safety of ivabradine in paediatric patients

I Marquínez-Alonso, S Manrique-Rodríguez… - European Journal of …, 2014 - ejhp.bmj.com
Background Ivabradine is authorised for the treatment of coronary artery disease and
chronic heart failure with systolic dysfunction in adult patients, but there is little information …

[HTML][HTML] Intervenciones farmacéuticas en las prescripciones de pacientes ingresados con insuficiencia renal crónica

P Arrabal-Durán, ME Durán-García… - Nefrología …, 2014 - SciELO Espana
ARRABAL-DURAN, Paula et al. Intervenciones farmacéuticas en las prescripciones de
pacientes ingresados con insuficiencia renal crónica. Nefrología (Madr.)[online]. 2014, vol …

DI-051 Effectiveness and safety of telaprevir and boceprevir for hepatitis C in liver transplant patients

ÁG Manzorro, C Rodríguez-González… - 2015 - ejhp.bmj.com
Background There are limited data that tackle safety and effectiveness of the triple treatment
based on protease inhibitors (telaprevir or boceprevir) in liver transplant patients. Purpose …

DGI-043 Increased Cost of Erythropoiesis-Stimulating Agents in Some Special Situations

V Escudero-Vilaplana, JM López-Gómez… - European Journal of …, 2013 - ejhp.bmj.com
Background Situations such as a previous kidney transplant or dialysis may increase the
dose requirement of erythropoiesis-stimulating agents (ESAs), which is associated with a …

DGI-009 Analysis of the Use of Erythropoiesis-Stimulating Agents in a University Hospital

V Escudero-Vilaplana, A Vega-Martínez… - European Journal of …, 2013 - ejhp.bmj.com
Background The use of erythropoiesis-stimulating agents (ESA) in the treatment of anaemia
due to chronic kidney disease (CKD) is highly variable regarding patient characteristics and …

CPC-006 Adequacy of Criteria For Starting Natalizumab in Patients with Multiple Sclerosis

BM Alfaro, ADL Pinto, MSP López… - European Journal of …, 2013 - ejhp.bmj.com
Background Natalizumab is a monoclonal antibody authorised as second-line treatment
after failure with interferon beta or in rapidly evolving severe relapsing-remitting multiple …

Level of concordance between two risk-assessment models for predicting venous thromboembolism in medical patients at admission

A De Lorenzo-Pinto, R García-Sánchez… - European Journal of …, 2016 - ejhp.bmj.com
Objectives To evaluate the level of concordance between the 2007 PRETEMED guidelines
and the 2012 American College of Chest Physicians (ACCP) guidelines in medical patients …

DGI-004 Analysis of Consultations Made by Patients in an Outpatient Service

IY Gomez, VE Vilaplana, IM Alonso… - European Journal of …, 2013 - ejhp.bmj.com
Background hospital pharmacists interview all outpatients with a new prescription, including
medication changes, and those who are suspected of not having good compliance …